1AD AdAlta

AdAlta (1AD): Initiation - Targeting IPF with its i-body platform

Edison Investment Research Limited
AdAlta (1AD): Initiation - Targeting IPF with its i-body platform

22-Feb-2021 / 20:00 GMT/BST

 

London, UK, 22 February 2021

 

 AdAlta (1AD): Initiation - Targeting IPF with its i-body platform

AdAlta is a clinical-stage company that uses its proprietary i-body discovery platform to target diseases, with an initial focus on conditions involving fibrosis. Its lead programme is AD-214, a C-X-C chemokine receptor type 4 (CXCR4) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF), which is in the healthy volunteer portion of a 98-subject Phase I trial. IPF is an orphan progressive lung disease that remains a significant unmet medical need, despite two approved blockbuster therapies, with median survival post-diagnosis of three to five years.

 

We value AdAlta at A$60m or A$0.25 per basic share using a risk-adjusted net present value (NPV) model. We only attribute value to AD-214 as it is the only programme in human clinical trials. The company had A$8.1m in cash at 31 December 2020 and we estimate will likely need to raise an additional A$11m through the end of FY23, barring additional licensing deals. 


to view the full report or to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Maxim Jacobs,

Nathaniel Calloway,

Learn more at and connect with Edison on: 

LinkedIn       

Twitter          

YouTube      


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

1169994  22-Feb-2021 

fncls.ssp?fn=show_t_gif&application_id=1169994&application_name=news&site_id=research_pool
EN
22/02/2021

Underlying

1ADAdAlta

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AdAlta

Sean Conroy
  • Sean Conroy
1AD ADALTA

AdAlta - Termination of coverage

Edison Investment Research is terminating coverage on AdAlta (1AD), Acorn Income Fund (AIF), GCP Student Living (DIGS) and Brighter (BRIG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

12/08/21 December 8, 2021 1 EN
Sean Conroy
  • Sean Conroy
1AD ADALTA

AdAlta - Termination of coverage

Edison Investment Research is terminating coverage on AdAlta (1AD), Acorn Income Fund (AIF), GCP Student Living (DIGS) and Brighter (BRIG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

12/08/21 December 8, 2021 1 EN
Sean Conroy
  • Sean Conroy
1AD ADALTA

AdAlta - Moving into CAR-T

AdAlta has announced a collaboration with Carina Biotech, a private Australian company, in which the two companies will work together to develop chimeric antigen receptor T cell (CAR-T) therapies for solid tumours. Under the agreement, AdAlta will discover and optimise proprietary i-bodies on up to five undisclosed tumour antigen targets, from which Carina will generate bi-specific CAR-T cells and identify optimal candidates. We believe the CAR-Ts will be autologous, generated from a patient’s o...

08/31/21 August 31, 2021 1 EN
Sean Conroy
  • Sean Conroy
1AD ADALTA

AdAlta - Moving into CAR-T

AdAlta has announced a collaboration with Carina Biotech, a private Australian company, in which the two companies will work together to develop chimeric antigen receptor T cell (CAR-T) therapies for solid tumours. Under the agreement, AdAlta will discover and optimise proprietary i-bodies on up to five undisclosed tumour antigen targets, from which Carina will generate bi-specific CAR-T cells and identify optimal candidates. We believe the CAR-Ts will be autologous, generated from a patient’s o...

08/31/21 August 31, 2021 1 EN
Sean Conroy
  • Sean Conroy
1AD ADALTA

AdAlta - Moving to an inhaled formulation

AdAlta has announced it will be moving forward with an inhaled formulation of AD-214 into efficacy studies in patients with idiopathic pulmonary fibrosis (IPF) rather than the original intravenous (IV) formulation. Preclinical studies with a radiolabelled version of AD-214 have indicated that IV dosing leads to much of the administered drug being rapidly distributed through the liver and cleared, rendering it unavailable to deliver a therapeutic effect. The company believes the advantages of an ...

07/22/21 July 22, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch